Related Experiment Video

Updated: Aug 17, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour

Y Greenman1, K Tordjman, E Osher

  • 1Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. greenman@tasmc.health.gov.il

Clinical Endocrinology
|June 21, 2005
PubMed
Abstract

Insights

Dopamine agonist (DA) treatment can prevent nonfunctioning pituitary adenoma (NFPA) remnant enlargement after surgery. Early DA intervention in NFPA patients significantly reduces tumor growth compared to delayed treatment or no treatment.

Area of Science:

  • Endocrinology
  • Neurosurgery
  • Oncology

Background:

  • Optimal postoperative management for nonfunctioning pituitary adenomas (NFPA) with residual tumor is debated.
  • Assessing dopamine agonist (DA) efficacy in preventing remnant enlargement is crucial.

Purpose of the Study:

  • To evaluate the effectiveness of dopamine agonist (DA) treatment in preventing the enlargement of residual nonfunctioning pituitary adenomas (NFPA) after surgical resection.

Main Methods:

  • A retrospective study comparing 33 patients treated with DA to 47 untreated patients.
  • Outcomes were analyzed based on the timing of DA initiation (upon detection vs. evident growth).

Main Results:

  • DA treatment significantly reduced tumor remnant enlargement compared to controls (P < 0.0001).
  • Early DA initiation (Group I) showed a hazard ratio of 0.135 for enlargement (P = 0.007).
  • Tumor enlargement-free survival was significantly longer in the early DA treatment group.

Conclusions:

  • Dopamine agonist therapy is associated with a reduced prevalence of residual tumor enlargement in NFPA patients.
  • Proactive DA treatment, initiated before evident remnant growth, offers the most significant benefit.

More Related Videos

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection02:22

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Published on: April 12, 2024

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...